A VISION Substudy of Reader Agreement on (68)Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for (177)Lu-PSMA-617 Radioligand Therapy

[ (68)Ga]Ga-PSMA-11 ( (68)Ga-PSMA-11) is used to identify prostate-specific membrane antigen (PSMA)–positive tumors on PET scans. In the VISION study, (68)Ga-PSMA-11 was used to determine the eligibility of patients with metastatic castration-resistant prostate cancer for treatment with [(177)Lu]Lu-...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuo, Phillip H., Yoo, Don C., Avery, Ryan, Seltzer, Marc, Calais, Jeremie, Nagarajah, James, Weber, Wolfgang A., Fendler, Wolfgang P., Hofman, Michael S., Krause, Bernd J., Brackman, Marcia, Kpamegan, Euloge, Ghebremariam, Samson, Benson, Taylor, Catafau, Ana M., Kendi, Ayse T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society of Nuclear Medicine 2023
Materias:
Clinical Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394308/
https://www.ncbi.nlm.nih.gov/pubmed/37230533
http://dx.doi.org/10.2967/jnumed.122.265077

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394308/
https://www.ncbi.nlm.nih.gov/pubmed/37230533
http://dx.doi.org/10.2967/jnumed.122.265077

Ejemplares similares